Transforming Lives,

Advancing Hope

2019 Janssen U.S. Transparency Report Watch the Video
“Patients and families in the United States continue to be concerned about their ability to access and afford their medications. At Janssen, we share those concerns. That’s why we continue to build on our leadership in transparency with our annual Janssen U.S. Transparency Report. The disclosures in this report demonstrate our responsible business practices that put patients first, and our continued commitment to contributing to sustainable, patient-centered solutions."
Scott White
Scott White Company Group Chairman North America Pharmaceuticals Johnson & Johnson

3 Things to Know about our 2019 U.S. Transparency Report

  • average medicine cost icon.svg
    For the third year in a row, the average net price of our medicines in the U.S. declined.
    Since our first U.S. Transparency Report in 2016, the compound net price of Janssen medicines declined 9.2% while the average net price of our medicines declined 1.2% in 2019.
  • Price-Tags.svg
    We provided intermediaries in the system with $24.5 billion in rebates, discounts, and fees — more than half the list price of our medicines.
    We offer discounts and rebates on our medicines so that payers will make them accessible and affordable. We believe they should share these savings directly with patients.
  • Beakers.svg
    Our investment in global research and development is 91% more than what we spent on global sales and marketing.
    In 2019, we invested $8.8 billion in global research and development. As a result, we had 2 new medicines and 9 new indications approved by the FDA, and this investment has built a pipeline of more than 80 medicine candidates.
We live in a moment of incredible hope, on the verge of extraordinary progress that could change our lives and the lives of our children and grandchildren. At Janssen, we are committed to bringing that promise to life.

Our approach to research today reflects our responsibility to take risks and push medicine beyond its current horizon, where tomorrow’s cures await. Sometimes, our quest for a cure is personal — like in the case of Gayle W., a Neuroscience Data Scientist at Janssen Research & Development, LLC, whose father recently passed away from Alzheimer’s disease.
Watch Gayle’s story to learn more.

Actions

Share the Report